Pharmacological Treatment of ADHD
First-Line Treatment: Stimulants
- The American Academy of Pediatrics recommends stimulant medications, such as methylphenidate and amphetamines, as the first-line pharmacological treatment for ADHD due to their large effect sizes and rapid onset of action 1
- Methylphenidate is typically the initial stimulant of choice for ADHD treatment, available in multiple formulations, with short-acting formulations providing 3-5 hours of symptom control, and long-acting/extended-release formulations providing day-long coverage 1, 2
- Common side effects of methylphenidate include decreased appetite, insomnia, headache, and potential cardiovascular effects, such as increased heart rate and blood pressure 3
- Growth effects, including height and weight, should be monitored in children taking methylphenidate, particularly during long-term treatment 1
Second-Line Treatment: Non-Stimulants
- Atomoxetine, a norepinephrine reuptake inhibitor, is recommended as a second-line treatment for ADHD, with a therapeutic effect that requires 6-12 weeks to develop 1, 5
- The FDA has issued a black box warning for atomoxetine due to an increased risk of suicidality, and patients should be monitored closely 1
- Alpha-2 adrenergic agonists, such as extended-release guanfacine and clonidine, are also recommended as second-line treatments, with a therapeutic effect that takes 2-4 weeks to develop 1, 3
- These medications may be particularly beneficial in patients with comorbid sleep disorders, tic disorders, or disruptive behavior disorders 3
Treatment Algorithm
- The treatment algorithm for ADHD recommends an initial assessment to confirm diagnosis using DSM criteria, screen for bipolar disorder, and assess for comorbidities that may influence treatment choice 1
- First-line treatment typically involves methylphenidate, preferably extended-release formulation, with gradual titration based on response and tolerability, and monitoring of height, weight, blood pressure, and pulse 1